← Leaderboards
Wilbur H. Chen
University Of Maryland Baltimore
$12,119,388
Attributed
$21,981,723
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.6M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,981,723 · 7
By mechanism
U01$10,535,442 · 2
R01$5,739,547 · 2
U19$5,461,650 · 2
M01$245,084 · 1
Top collaborators
- Eileen M. Barry9 shared
- Claire M Fraser-Liggett5 shared
- Karen L. Kotloff5 shared
- Alexander Sulakvelidze5 shared
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- Marcelo B. Sztein$36,733,861
- James B Kaper$25,841,976
- James P. Nataro$22,975,369
- Marcela F Pasetti$26,884,335
- Myron Max Levine$22,681,817
Others in their field
Top investigators on “Vaccines”
- Lawrence Corey · Fred Hutchinson Cancer Center$829,044,908
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$556,540,832
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$515,215,260
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
- Dennis R. Burton · Scripps Research Institute$316,106,418
Research focus
VaccinesSafetyEnsureVaccine DevelopmentClinical TrialsGood Clinical PracticeSeriesChildShigellaRandomizedPreventEnteric PathogenInpatientsDeveloping CountriesProtocols DocumentationDiarrheaInstitutional Review BoardsInfectionMedicalShigella FlexneriGuidelinesMarylandUniversitiesProcedures
Grant awards (22)
Advanced Development of a Combined Shigella-ETEC Vaccine$1,098,552
R01 · FY2025 · AI
Clinical and Biostatistics Core$609,199
U19 · FY2025 · AI · contact PI
Clinical Core$208,221
U19 · FY2025 · AI · contact PI
Bacteriophage-based approach for managing Shigella infections$1,162,758
U01 · FY2024 · AI
Advanced Development of a Combined Shigella-ETEC Vaccine$1,115,547
R01 · FY2024 · AI
Clinical and Biostatistics Core$372,650
U19 · FY2024 · AI · contact PI
Clinical Core$205,555
U19 · FY2024 · AI · contact PI
Clinical and Biostatistics Core$1,638,052
U19 · FY2023 · AI · contact PI
Bacteriophage-based approach for managing Shigella infections$1,172,622
U01 · FY2023 · AI
Advanced Development of a Combined Shigella-ETEC Vaccine$1,053,471
R01 · FY2023 · AI
Initial clinical evaluation of attenuated Shigella flexneri 2a live vector expressing enterotoxigenic Escherichia coli antigens, strain CVD 1208S-122.$715,435
U01 · FY2023 · AI · contact PI
Clinical and Biostatistics Core$1,405,948
U19 · FY2022 · AI · contact PI
Bacteriophage-based approach for managing Shigella infections$1,171,611
U01 · FY2022 · AI
Initial clinical evaluation of attenuated Shigella flexneri 2a live vector expressing enterotoxigenic Escherichia coli antigens, strain CVD 1208S-122.$1,529,187
U01 · FY2021 · AI · contact PI
Bacteriophage-based approach for managing Shigella infections$1,439,728
U01 · FY2021 · AI
Clinical and Biostatistics Core$1,022,025
U19 · FY2021 · AI · contact PI
Bacteriophage-based approach for managing Shigella infections$1,952,644
U01 · FY2020 · AI
Initial clinical evaluation of attenuated Shigella flexneri 2a live vector expressing enterotoxigenic Escherichia coli antigens, strain CVD 1208S-122.$1,391,457
U01 · FY2020 · AI · contact PI
Good Manufacturing Practices Master Cell and Working Cell Banks and GMP Pilot Lot of Prototype Shigella flexneri 2a live vector expressing enterotoxigenic E. coli antigens, CVD 1208S 122$445,597
R01 · FY2019 · AI
Good Manufacturing Practices Master Cell and Working Cell Banks and GMP Pilot Lot of Prototype Shigella flexneri 2a live vector expressing enterotoxigenic E. coli antigens, CVD 1208S 122$1,062,611
R01 · FY2018 · AI
Good Manufacturing Practices Master Cell and Working Cell Banks and GMP Pilot Lot of Prototype Shigella flexneri 2a live vector expressing enterotoxigenic E. coli antigens, CVD 1208S 122$963,769
R01 · FY2017 · AI
CLINICAL TRIAL: PHASE I/II STUDY OF A BOOSTER DOSE OF A/H5N1/INDONESIA/05/05 (CL$245,084
M01 · FY2009 · RR · contact PI